Puma Biotechnology | Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amgen USD 3.96B 464M 2025-12
Biogen USD 659.6M 192.2M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
Esperion Therapeutics USD -16.03M 18.6M 2024-09
Exelixis USD 235.91M 20.45M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Glaxosmithkline GBP 3.76B 1.32B 2025-09
Incyte USD 383.88M 47.43M 2025-12
MacroGenics USD 18.64M 55.4M 2025-09
Moderna USD -857M 597M 2025-12
Novartis USD 4.5B 363M 2025-09
Pfizer USD 4.65B 3.99B 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Takeda JPY 168.82B 479.89B 2025-12
TG Therapeutics USD 50.49M 21.13M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12


Puma Biotechnology Le Bénéfice D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.